Niagen Bioscience, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $27.2 million (-20.0% year over year) and diluted EPS of -$0.01. It usually reports 35–63 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 3, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Mar 4, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–63 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
27
-20.0%
|
-1
-125.6%
|
-0.01
-120.0%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
30
-4.3%
|
1
-73.3%
|
0.01
-75.0%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
31
+3.3%
|
6
+24.8%
|
0.07
+16.7%
|
|
Mar 4, 2026
63 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
34
+16.2%
|
4
-42.4%
|
0.05
-44.6%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
34
+32.9%
|
5
+143.8%
|
0.05
+150.0%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
31
+36.8%
|
4
+24160.0%
|
0.04
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
30
+37.6%
|
5
+1129.1%
|
0.06
+700.0%
|
|
Mar 4, 2025
63 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
29
+37.4%
|
7
+6197.4%
|
0.09
+5666.1%
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NAGE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1386570
- Former names
- ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.